Study design and rationale for a randomised, placebo-controlled, double-blind study to assess the efficacy of selumetinib (AZD6244; ARRY-142886) in combination ... View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2015-06-10

AUTHORS

Richard D. Carvajal, Gary K. Schwartz, Helen Mann, Ian Smith, Paul D. Nathan

ABSTRACT

BackgroundUveal melanoma is characterised by mutations in GNAQ and GNA11, resulting in Ras/Raf/MEK/ERK pathway activation. Treatment with selumetinib (AZD6244, ARRY-142886), a MEK1/2 inhibitor, results in antitumour effects in uveal melanoma pre-clinical models. A randomised phase II trial demonstrated improved progression-free survival (PFS) and response rate (RR) with selumetinib monotherapy versus chemotherapy with temozolomide or dacarbazine in patients with metastatic uveal melanoma. Pre-clinically, selumetinib in combination with alkylating agents enhanced antitumour activity compared with chemotherapy alone. We hypothesise that selumetinib in combination with dacarbazine will result in improved clinical outcomes in patients with metastatic uveal melanoma versus dacarbazine alone.Methods/DesignSUMIT is a randomised, international, double-blind, placebo-controlled, phase III study assessing the efficacy and safety of selumetinib in combination with dacarbazine in patients with metastatic uveal melanoma who have not received prior systemic therapy. Primary endpoint is PFS. Secondary endpoints include objective RR, duration of response, change in tumour size at Week 6, overall survival, safety and tolerability. Exploratory endpoints include efficacy in tumours with GNAQ or GNA11 mutations. Eligible patients must have: ≥1 lesion that can be accurately measured at baseline, and is suitable for accurate repeated measurements; ECOG performance status 0–1; life expectancy >12 weeks. Mutation status for GNAQ/GNA11 will be assessed retrospectively.An estimated 128 patients from approximately 50 sites globally will be randomised (3:1) to selumetinib 75 mg twice daily or placebo in combination with dacarbazine 1000 mg/m2 on Day 1 of every 21-day cycle until objective disease progression, intolerable toxicity or occurrence of another discontinuation criterion. Randomisation will be stratified by the presence/absence of liver metastases. Tumours will be evaluated by RECIST v1.1 every 6 weeks. All patients have the option of receiving selumetinib with or without dacarbazine at disease progression. Study enrolment began in April 2014 and is expected to complete in early 2015.DiscussionTreatment of patients with metastatic uveal melanoma represents an area of high unmet medical need. This study evaluating selumetinib in combination with dacarbazine was designed with input from the US FDA, and is the first potential registration trial to be conducted in patients with metastatic uveal melanoma.Trial registrationClinicaltrials.gov (Date of registration, October 10, 2013)Registration number: NCT01974752Trial abbreviation: SUMIT More... »

PAGES

467

Identifiers

URI

http://scigraph.springernature.com/pub.10.1186/s12885-015-1470-z

DOI

http://dx.doi.org/10.1186/s12885-015-1470-z

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1019011971

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/26059332


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Oncology and Carcinogenesis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adult", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antineoplastic Combined Chemotherapy Protocols", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Benzimidazoles", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Dacarbazine", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Disease-Free Survival", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Melanoma", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Neoplasm Metastasis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Uveal Neoplasms", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Division of Hematology/Oncology, Columbia University Medical Center, 10032, New York, NY, USA", 
          "id": "http://www.grid.ac/institutes/grid.239585.0", 
          "name": [
            "Division of Hematology/Oncology, Columbia University Medical Center, 10032, New York, NY, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Carvajal", 
        "givenName": "Richard D.", 
        "id": "sg:person.0726366600.25", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0726366600.25"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Division of Hematology/Oncology, Columbia University Medical Center, 10032, New York, NY, USA", 
          "id": "http://www.grid.ac/institutes/grid.239585.0", 
          "name": [
            "Division of Hematology/Oncology, Columbia University Medical Center, 10032, New York, NY, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Schwartz", 
        "givenName": "Gary K.", 
        "id": "sg:person.012707142152.08", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.012707142152.08"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "AstraZeneca, Macclesfield, UK", 
          "id": "http://www.grid.ac/institutes/grid.417815.e", 
          "name": [
            "AstraZeneca, Macclesfield, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Mann", 
        "givenName": "Helen", 
        "id": "sg:person.01057316056.72", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01057316056.72"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "AstraZeneca, Macclesfield, UK", 
          "id": "http://www.grid.ac/institutes/grid.417815.e", 
          "name": [
            "AstraZeneca, Macclesfield, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Smith", 
        "givenName": "Ian", 
        "id": "sg:person.016301514162.37", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.016301514162.37"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Mt Vernon Cancer Centre, Northwood, UK", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "Mt Vernon Cancer Centre, Northwood, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Nathan", 
        "givenName": "Paul D.", 
        "id": "sg:person.01253517277.15", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01253517277.15"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1038/sj.bjc.6602598", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1051793685", 
          "https://doi.org/10.1038/sj.bjc.6602598"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/sj.bjc.6600521", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1041921447", 
          "https://doi.org/10.1038/sj.bjc.6600521"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/sj.bjc.6605226", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1036114162", 
          "https://doi.org/10.1038/sj.bjc.6605226"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00262-011-1089-0", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1046605974", 
          "https://doi.org/10.1007/s00262-011-1089-0"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/bjc.2012.8", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1019390006", 
          "https://doi.org/10.1038/bjc.2012.8"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/nature08833", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1009288742", 
          "https://doi.org/10.1038/nature08833"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/nature08902", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1006916541", 
          "https://doi.org/10.1038/nature08902"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2015-06-10", 
    "datePublishedReg": "2015-06-10", 
    "description": "BackgroundUveal melanoma is characterised by mutations in GNAQ and GNA11, resulting in Ras/Raf/MEK/ERK pathway activation. Treatment with selumetinib (AZD6244, ARRY-142886), a MEK1/2 inhibitor, results in antitumour effects in uveal melanoma pre-clinical models. A randomised phase II trial demonstrated improved progression-free survival (PFS) and response rate (RR) with selumetinib monotherapy versus chemotherapy with temozolomide or dacarbazine in patients with metastatic uveal melanoma. Pre-clinically, selumetinib in combination with alkylating agents enhanced antitumour activity compared with chemotherapy alone. We hypothesise that selumetinib in combination with dacarbazine will result in improved clinical outcomes in patients with metastatic uveal melanoma versus dacarbazine alone.Methods/DesignSUMIT is a randomised, international, double-blind, placebo-controlled, phase III study assessing the efficacy and safety of selumetinib in combination with dacarbazine in patients with metastatic uveal melanoma who have not received prior systemic therapy. Primary endpoint is PFS. Secondary endpoints include objective RR, duration of response, change in tumour size at Week 6, overall survival, safety and tolerability. Exploratory endpoints include efficacy in tumours with GNAQ or GNA11 mutations. Eligible patients must have: \u22651 lesion that can be accurately measured at baseline, and is suitable for accurate repeated measurements; ECOG performance status 0\u20131; life expectancy >12\u00a0weeks. Mutation status for GNAQ/GNA11 will be assessed retrospectively.An estimated 128 patients from approximately 50 sites globally will be randomised (3:1) to selumetinib 75\u00a0mg twice daily or placebo in combination with dacarbazine 1000\u00a0mg/m2 on Day 1 of every 21-day cycle until objective disease progression, intolerable toxicity or occurrence of another discontinuation criterion. Randomisation will be stratified by the presence/absence of liver metastases. Tumours will be evaluated by RECIST v1.1 every 6\u00a0weeks. All patients have the option of receiving selumetinib with or without dacarbazine at disease progression. Study enrolment began in April 2014 and is expected to complete in early 2015.DiscussionTreatment of patients with metastatic uveal melanoma represents an area of high unmet medical need. This study evaluating selumetinib in combination with dacarbazine was designed with input from the US FDA, and is the first potential registration trial to be conducted in patients with metastatic uveal melanoma.Trial registrationClinicaltrials.gov (Date of registration, October 10, 2013)Registration number: NCT01974752Trial abbreviation: SUMIT", 
    "genre": "article", 
    "id": "sg:pub.10.1186/s12885-015-1470-z", 
    "isAccessibleForFree": true, 
    "isPartOf": [
      {
        "id": "sg:journal.1024632", 
        "issn": [
          "1471-2407"
        ], 
        "name": "BMC Cancer", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "1", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "15"
      }
    ], 
    "keywords": [
      "metastatic uveal melanoma", 
      "progression-free survival", 
      "uveal melanoma", 
      "response rate", 
      "disease progression", 
      "randomised phase II trial", 
      "ECOG performance status 0", 
      "improved progression-free survival", 
      "high unmet medical need", 
      "safety of selumetinib", 
      "performance status 0", 
      "efficacy of selumetinib", 
      "objective response rate", 
      "phase II trial", 
      "double-blind study", 
      "duration of response", 
      "objective disease progression", 
      "improved clinical outcomes", 
      "MEK/ERK pathway activation", 
      "pre-clinical models", 
      "date of registration", 
      "unmet medical need", 
      "GNAQ/GNA11", 
      "RAF/MEK/ERK pathway activation", 
      "exploratory endpoints", 
      "eligible patients", 
      "status 0", 
      "RECIST v1.1", 
      "II trial", 
      "primary endpoint", 
      "secondary endpoints", 
      "intolerable toxicity", 
      "ERK pathway activation", 
      "systemic therapy", 
      "overall survival", 
      "liver metastases", 
      "clinical outcomes", 
      "study enrollment", 
      "tumor size", 
      "discontinuation criteria", 
      "antitumour effect", 
      "week 6", 
      "patients", 
      "dacarbazine", 
      "mutation status", 
      "day 1", 
      "registration trials", 
      "selumetinib", 
      "melanoma", 
      "medical need", 
      "GNA11 mutations", 
      "antitumour activity", 
      "US FDA", 
      "BackgroundUveal melanoma", 
      "study design", 
      "pathway activation", 
      "MEK1/2 inhibitor", 
      "life expectancy", 
      "endpoint", 
      "chemotherapy", 
      "efficacy", 
      "tumors", 
      "GNA11", 
      "trials", 
      "progression", 
      "weeks", 
      "GNAQ", 
      "survival", 
      "presence/absence", 
      "safety", 
      "monotherapy", 
      "tolerability", 
      "placebo", 
      "randomisation", 
      "metastasis", 
      "therapy", 
      "lesions", 
      "mutations", 
      "baseline", 
      "study", 
      "FDA", 
      "outcomes", 
      "treatment", 
      "enrollment", 
      "inhibitors", 
      "toxicity", 
      "duration", 
      "activation", 
      "v1.1", 
      "expectancy", 
      "combination", 
      "status", 
      "options", 
      "agents", 
      "response", 
      "rationale", 
      "absence", 
      "criteria", 
      "activity", 
      "occurrence", 
      "rate", 
      "date", 
      "m2", 
      "effect", 
      "changes", 
      "need", 
      "registration", 
      "sites", 
      "number", 
      "area", 
      "results", 
      "cycle", 
      "abbreviations", 
      "size", 
      "measurements", 
      "model", 
      "design", 
      "input"
    ], 
    "name": "Study design and rationale for a randomised, placebo-controlled, double-blind study to assess the efficacy of selumetinib (AZD6244; ARRY-142886) in combination with dacarbazine in patients with metastatic uveal melanoma (SUMIT)", 
    "pagination": "467", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1019011971"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1186/s12885-015-1470-z"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "26059332"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1186/s12885-015-1470-z", 
      "https://app.dimensions.ai/details/publication/pub.1019011971"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-12-01T06:34", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20221201/entities/gbq_results/article/article_680.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1186/s12885-015-1470-z"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1186/s12885-015-1470-z'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1186/s12885-015-1470-z'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1186/s12885-015-1470-z'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1186/s12885-015-1470-z'


 

This table displays all metadata directly associated to this object as RDF triples.

292 TRIPLES      21 PREDICATES      163 URIs      148 LITERALS      20 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1186/s12885-015-1470-z schema:about N05c3ada7f77d40338f3b135c0e4b7604
2 N096397c06bcb4a72ab5b29b16e72fc3b
3 N1eecf8c8ea344251972c6dc88f4f6809
4 N43ed0795af644ea791407e2c0d1e32bc
5 N4411d4c90c7b46dea2e6b7fba57e0469
6 N54f97e6103a94bff9ffb0dab49be1194
7 N7e995c2904774c51a07725b2c7967f3b
8 N83cadf8c5408491e9ff4775c4e18a5a9
9 N87a9a0f353754a2ba9593431ef9c83e4
10 N9ec86f6a2a424e6dbe027c1a62527234
11 Nb1e4bf2856dc4d0d9884ae6fab68b432
12 Nc2866edc4414403f98e3e723b8ab22fd
13 Ne84ed780aadd4fd283f911607a4d743d
14 anzsrc-for:11
15 anzsrc-for:1112
16 schema:author N8ebde1de2a494ec6a9870d9801e70ed5
17 schema:citation sg:pub.10.1007/s00262-011-1089-0
18 sg:pub.10.1038/bjc.2012.8
19 sg:pub.10.1038/nature08833
20 sg:pub.10.1038/nature08902
21 sg:pub.10.1038/sj.bjc.6600521
22 sg:pub.10.1038/sj.bjc.6602598
23 sg:pub.10.1038/sj.bjc.6605226
24 schema:datePublished 2015-06-10
25 schema:datePublishedReg 2015-06-10
26 schema:description BackgroundUveal melanoma is characterised by mutations in GNAQ and GNA11, resulting in Ras/Raf/MEK/ERK pathway activation. Treatment with selumetinib (AZD6244, ARRY-142886), a MEK1/2 inhibitor, results in antitumour effects in uveal melanoma pre-clinical models. A randomised phase II trial demonstrated improved progression-free survival (PFS) and response rate (RR) with selumetinib monotherapy versus chemotherapy with temozolomide or dacarbazine in patients with metastatic uveal melanoma. Pre-clinically, selumetinib in combination with alkylating agents enhanced antitumour activity compared with chemotherapy alone. We hypothesise that selumetinib in combination with dacarbazine will result in improved clinical outcomes in patients with metastatic uveal melanoma versus dacarbazine alone.Methods/DesignSUMIT is a randomised, international, double-blind, placebo-controlled, phase III study assessing the efficacy and safety of selumetinib in combination with dacarbazine in patients with metastatic uveal melanoma who have not received prior systemic therapy. Primary endpoint is PFS. Secondary endpoints include objective RR, duration of response, change in tumour size at Week 6, overall survival, safety and tolerability. Exploratory endpoints include efficacy in tumours with GNAQ or GNA11 mutations. Eligible patients must have: ≥1 lesion that can be accurately measured at baseline, and is suitable for accurate repeated measurements; ECOG performance status 0–1; life expectancy >12 weeks. Mutation status for GNAQ/GNA11 will be assessed retrospectively.An estimated 128 patients from approximately 50 sites globally will be randomised (3:1) to selumetinib 75 mg twice daily or placebo in combination with dacarbazine 1000 mg/m2 on Day 1 of every 21-day cycle until objective disease progression, intolerable toxicity or occurrence of another discontinuation criterion. Randomisation will be stratified by the presence/absence of liver metastases. Tumours will be evaluated by RECIST v1.1 every 6 weeks. All patients have the option of receiving selumetinib with or without dacarbazine at disease progression. Study enrolment began in April 2014 and is expected to complete in early 2015.DiscussionTreatment of patients with metastatic uveal melanoma represents an area of high unmet medical need. This study evaluating selumetinib in combination with dacarbazine was designed with input from the US FDA, and is the first potential registration trial to be conducted in patients with metastatic uveal melanoma.Trial registrationClinicaltrials.gov (Date of registration, October 10, 2013)Registration number: NCT01974752Trial abbreviation: SUMIT
27 schema:genre article
28 schema:isAccessibleForFree true
29 schema:isPartOf N131ff73979464f34aaac49336873ee72
30 Nf49efabfa2c346b5ba5104754410a200
31 sg:journal.1024632
32 schema:keywords BackgroundUveal melanoma
33 ECOG performance status 0
34 ERK pathway activation
35 FDA
36 GNA11
37 GNA11 mutations
38 GNAQ
39 GNAQ/GNA11
40 II trial
41 MEK/ERK pathway activation
42 MEK1/2 inhibitor
43 RAF/MEK/ERK pathway activation
44 RECIST v1.1
45 US FDA
46 abbreviations
47 absence
48 activation
49 activity
50 agents
51 antitumour activity
52 antitumour effect
53 area
54 baseline
55 changes
56 chemotherapy
57 clinical outcomes
58 combination
59 criteria
60 cycle
61 dacarbazine
62 date
63 date of registration
64 day 1
65 design
66 discontinuation criteria
67 disease progression
68 double-blind study
69 duration
70 duration of response
71 effect
72 efficacy
73 efficacy of selumetinib
74 eligible patients
75 endpoint
76 enrollment
77 expectancy
78 exploratory endpoints
79 high unmet medical need
80 improved clinical outcomes
81 improved progression-free survival
82 inhibitors
83 input
84 intolerable toxicity
85 lesions
86 life expectancy
87 liver metastases
88 m2
89 measurements
90 medical need
91 melanoma
92 metastasis
93 metastatic uveal melanoma
94 model
95 monotherapy
96 mutation status
97 mutations
98 need
99 number
100 objective disease progression
101 objective response rate
102 occurrence
103 options
104 outcomes
105 overall survival
106 pathway activation
107 patients
108 performance status 0
109 phase II trial
110 placebo
111 pre-clinical models
112 presence/absence
113 primary endpoint
114 progression
115 progression-free survival
116 randomisation
117 randomised phase II trial
118 rate
119 rationale
120 registration
121 registration trials
122 response
123 response rate
124 results
125 safety
126 safety of selumetinib
127 secondary endpoints
128 selumetinib
129 sites
130 size
131 status
132 status 0
133 study
134 study design
135 study enrollment
136 survival
137 systemic therapy
138 therapy
139 tolerability
140 toxicity
141 treatment
142 trials
143 tumor size
144 tumors
145 unmet medical need
146 uveal melanoma
147 v1.1
148 week 6
149 weeks
150 schema:name Study design and rationale for a randomised, placebo-controlled, double-blind study to assess the efficacy of selumetinib (AZD6244; ARRY-142886) in combination with dacarbazine in patients with metastatic uveal melanoma (SUMIT)
151 schema:pagination 467
152 schema:productId N0cdf820d01974bf6bdd10d523b347548
153 N50484da52d1d49858d6c0582393749d7
154 Nc3ed4da0c5d54795bf446e33d268564b
155 schema:sameAs https://app.dimensions.ai/details/publication/pub.1019011971
156 https://doi.org/10.1186/s12885-015-1470-z
157 schema:sdDatePublished 2022-12-01T06:34
158 schema:sdLicense https://scigraph.springernature.com/explorer/license/
159 schema:sdPublisher Nd305a2dc480e43b6a8f80d200f2715e6
160 schema:url https://doi.org/10.1186/s12885-015-1470-z
161 sgo:license sg:explorer/license/
162 sgo:sdDataset articles
163 rdf:type schema:ScholarlyArticle
164 N05c3ada7f77d40338f3b135c0e4b7604 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
165 schema:name Male
166 rdf:type schema:DefinedTerm
167 N096397c06bcb4a72ab5b29b16e72fc3b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
168 schema:name Adult
169 rdf:type schema:DefinedTerm
170 N0bb7249ae2904bbca287eea3ee323972 rdf:first sg:person.01253517277.15
171 rdf:rest rdf:nil
172 N0cdf820d01974bf6bdd10d523b347548 schema:name pubmed_id
173 schema:value 26059332
174 rdf:type schema:PropertyValue
175 N131ff73979464f34aaac49336873ee72 schema:issueNumber 1
176 rdf:type schema:PublicationIssue
177 N1eecf8c8ea344251972c6dc88f4f6809 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
178 schema:name Middle Aged
179 rdf:type schema:DefinedTerm
180 N25bc4287cfdf448aa56cdc37d8dc9e56 rdf:first sg:person.01057316056.72
181 rdf:rest Na221b0a14d5e47eaadc8eefdf626d339
182 N43ed0795af644ea791407e2c0d1e32bc schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
183 schema:name Uveal Neoplasms
184 rdf:type schema:DefinedTerm
185 N4411d4c90c7b46dea2e6b7fba57e0469 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
186 schema:name Aged
187 rdf:type schema:DefinedTerm
188 N50484da52d1d49858d6c0582393749d7 schema:name doi
189 schema:value 10.1186/s12885-015-1470-z
190 rdf:type schema:PropertyValue
191 N54f97e6103a94bff9ffb0dab49be1194 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
192 schema:name Benzimidazoles
193 rdf:type schema:DefinedTerm
194 N7e995c2904774c51a07725b2c7967f3b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
195 schema:name Female
196 rdf:type schema:DefinedTerm
197 N83cadf8c5408491e9ff4775c4e18a5a9 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
198 schema:name Humans
199 rdf:type schema:DefinedTerm
200 N87a9a0f353754a2ba9593431ef9c83e4 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
201 schema:name Neoplasm Metastasis
202 rdf:type schema:DefinedTerm
203 N8ebde1de2a494ec6a9870d9801e70ed5 rdf:first sg:person.0726366600.25
204 rdf:rest Nd34ebd3720bc4dde891cf512a94b06b5
205 N9ec86f6a2a424e6dbe027c1a62527234 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
206 schema:name Dacarbazine
207 rdf:type schema:DefinedTerm
208 Na221b0a14d5e47eaadc8eefdf626d339 rdf:first sg:person.016301514162.37
209 rdf:rest N0bb7249ae2904bbca287eea3ee323972
210 Nb1e4bf2856dc4d0d9884ae6fab68b432 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
211 schema:name Antineoplastic Combined Chemotherapy Protocols
212 rdf:type schema:DefinedTerm
213 Nc2866edc4414403f98e3e723b8ab22fd schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
214 schema:name Melanoma
215 rdf:type schema:DefinedTerm
216 Nc3ed4da0c5d54795bf446e33d268564b schema:name dimensions_id
217 schema:value pub.1019011971
218 rdf:type schema:PropertyValue
219 Nd305a2dc480e43b6a8f80d200f2715e6 schema:name Springer Nature - SN SciGraph project
220 rdf:type schema:Organization
221 Nd34ebd3720bc4dde891cf512a94b06b5 rdf:first sg:person.012707142152.08
222 rdf:rest N25bc4287cfdf448aa56cdc37d8dc9e56
223 Ne84ed780aadd4fd283f911607a4d743d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
224 schema:name Disease-Free Survival
225 rdf:type schema:DefinedTerm
226 Nf49efabfa2c346b5ba5104754410a200 schema:volumeNumber 15
227 rdf:type schema:PublicationVolume
228 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
229 schema:name Medical and Health Sciences
230 rdf:type schema:DefinedTerm
231 anzsrc-for:1112 schema:inDefinedTermSet anzsrc-for:
232 schema:name Oncology and Carcinogenesis
233 rdf:type schema:DefinedTerm
234 sg:journal.1024632 schema:issn 1471-2407
235 schema:name BMC Cancer
236 schema:publisher Springer Nature
237 rdf:type schema:Periodical
238 sg:person.01057316056.72 schema:affiliation grid-institutes:grid.417815.e
239 schema:familyName Mann
240 schema:givenName Helen
241 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01057316056.72
242 rdf:type schema:Person
243 sg:person.01253517277.15 schema:affiliation grid-institutes:None
244 schema:familyName Nathan
245 schema:givenName Paul D.
246 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01253517277.15
247 rdf:type schema:Person
248 sg:person.012707142152.08 schema:affiliation grid-institutes:grid.239585.0
249 schema:familyName Schwartz
250 schema:givenName Gary K.
251 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.012707142152.08
252 rdf:type schema:Person
253 sg:person.016301514162.37 schema:affiliation grid-institutes:grid.417815.e
254 schema:familyName Smith
255 schema:givenName Ian
256 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.016301514162.37
257 rdf:type schema:Person
258 sg:person.0726366600.25 schema:affiliation grid-institutes:grid.239585.0
259 schema:familyName Carvajal
260 schema:givenName Richard D.
261 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0726366600.25
262 rdf:type schema:Person
263 sg:pub.10.1007/s00262-011-1089-0 schema:sameAs https://app.dimensions.ai/details/publication/pub.1046605974
264 https://doi.org/10.1007/s00262-011-1089-0
265 rdf:type schema:CreativeWork
266 sg:pub.10.1038/bjc.2012.8 schema:sameAs https://app.dimensions.ai/details/publication/pub.1019390006
267 https://doi.org/10.1038/bjc.2012.8
268 rdf:type schema:CreativeWork
269 sg:pub.10.1038/nature08833 schema:sameAs https://app.dimensions.ai/details/publication/pub.1009288742
270 https://doi.org/10.1038/nature08833
271 rdf:type schema:CreativeWork
272 sg:pub.10.1038/nature08902 schema:sameAs https://app.dimensions.ai/details/publication/pub.1006916541
273 https://doi.org/10.1038/nature08902
274 rdf:type schema:CreativeWork
275 sg:pub.10.1038/sj.bjc.6600521 schema:sameAs https://app.dimensions.ai/details/publication/pub.1041921447
276 https://doi.org/10.1038/sj.bjc.6600521
277 rdf:type schema:CreativeWork
278 sg:pub.10.1038/sj.bjc.6602598 schema:sameAs https://app.dimensions.ai/details/publication/pub.1051793685
279 https://doi.org/10.1038/sj.bjc.6602598
280 rdf:type schema:CreativeWork
281 sg:pub.10.1038/sj.bjc.6605226 schema:sameAs https://app.dimensions.ai/details/publication/pub.1036114162
282 https://doi.org/10.1038/sj.bjc.6605226
283 rdf:type schema:CreativeWork
284 grid-institutes:None schema:alternateName Mt Vernon Cancer Centre, Northwood, UK
285 schema:name Mt Vernon Cancer Centre, Northwood, UK
286 rdf:type schema:Organization
287 grid-institutes:grid.239585.0 schema:alternateName Division of Hematology/Oncology, Columbia University Medical Center, 10032, New York, NY, USA
288 schema:name Division of Hematology/Oncology, Columbia University Medical Center, 10032, New York, NY, USA
289 rdf:type schema:Organization
290 grid-institutes:grid.417815.e schema:alternateName AstraZeneca, Macclesfield, UK
291 schema:name AstraZeneca, Macclesfield, UK
292 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...